NYSE$IBIO

iBio Inc · Q1 2026 earnings

Q1 2026 earnings · · After market close · Investor relations

Briefing

IBIO reported Q1 2026 a net loss of $5.7M.

For Q1 2026, IBIO reported net loss was $5.7M. The filing discusses operating performance, liquidity, and outlook in MD&A.

  • Net loss $5.7M.
  • MD&A covers R&D, cash runway, and sector-specific risks.
  • MD&A covers R&D, cash runway, and sector-specific risks.

Headline financials

Total Revenue

$100K

Previous: $0.00
EPS (adj)

-$0.11

Previous: -$0.46+76.1%
Capital Expenditures

-$32K

Previous: $0.00
Free Cash Flow

-$5.75M

Previous: -$3.99M-44.2%
Net Income

-$5.72M

Previous: -$3.99M-43.4%
Operating Income

-$5.95M

Previous: -$4.11M-44.9%
Cash & Equivalents

$28.1M

Previous: $11M+154.7%
Total Assets

$64.2M

Previous: $24.5M+161.7%

Revenue & EPS history

iBio · Revenue · Quarterly

$100K

Q1 2026
Beat estimate in 2 of 7 quarters(29%)
ActualEstimate

Forward guidance

Outlook focuses on cash runway, pipeline milestones, and cost discipline as the company works toward profitability.

Tailwinds

  • Cash and equivalents support operations into upcoming milestones.
  • Clinical or product pipeline progress noted in MD&A.

Headwinds

  • Ongoing operating losses and R&D spend pressure near-term earnings.
  • Financing, dilution, or partnership timing may affect liquidity.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2026

Historical avgQ1 2026

-1.4%

Avg return

Earnings day

-2.9%

Avg return

5 days after

+14.3%

Avg return

30 days after

43%

17 / 40 earnings

Positive

+24.4%

Q3 2020

Best reaction

-34.4%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026+12.9%+9.9%+22.8%
Q1 2026-8.0%-3.2%+55.2%
Q4 2025+3.7%+8.6%+6.2%
Q3 2025+1.3%+1.3%+30.4%
Q2 2025-14.8%-7.8%+49.2%
Q1 2025-9.4%-10.9%-2.0%
Q4 2024-2.6%-4.2%+51.1%
Q3 2026-3.7%+23.9%+36.2%
Q3 2024+1.6%+7.0%+37.8%
Q2 2024+5.2%+5.2%+2.6%
Q1 2024-3.4%-10.3%-78.1%
Q4 2023-3.3%-9.1%-6.1%
Q3 2023-7.9%-5.9%-31.7%
Q2 2023-10.5%+55.8%+113.7%
Q1 2023+0.0%-8.6%-68.6%
Q4 2022-34.4%-46.9%-74.6%
Q3 2022+0.0%+0.0%+12.0%
Q2 2022+2.7%-8.1%-5.4%
Q1 2022-9.2%-11.8%-17.1%
Q4 2021-4.3%-11.1%-35.0%
Q3 2021-6.8%-0.7%+5.4%
Q2 2021-15.3%-17.8%-29.8%
Q1 2021+15.2%-9.6%-38.2%
Q3 2020+24.4%+16.0%+31.9%
Q2 2020-10.5%-21.1%+321.1%
Q1 2020+13.3%-26.7%+46.7%
Q3 2019+7.3%-2.4%-4.9%
Q2 2019-2.2%-4.4%-6.7%
Q1 2019+4.0%+9.3%-10.7%
Q1 2015+3.4%
Q1 2014+0.0%
Q1 2013-1.9%
Q3 2012-9.8%
Q1 2010+1.8%
Q1 2012+1.8%
Q4 2011-3.0%
Q3 2011+4.8%
Q2 2010+3.4%
Q4 2010+1.4%
Q3 2010-1.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro